BioSpace News Archive

Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled Medicare Advantage company, will release its fourth quarter and full-year 2021 financial results on Thursday, March 3, 2022, after market close.

Boehringer Ingelheim (Canada) Ltd. and the pan-Canadian Pharmaceutical Alliance (pCPA) have completed negotiations for OFEV® (nintedanib), a multi-targeted tyrosine kinase inhibitor for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD).

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced that it has appointed Eddie C. Cheung, M.D., FACG, to lead Strategic Medical Affairs in Asia.

Centene Corporation (NYSE: CNC) today announced that the National Committee for Quality Assurance (NCQA) has awarded Trillium Community Health Plan a Health Plan Accreditation status of “Accredited” for the Medicaid product.

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation, provided an update on its oral feasibility programs involving the Company’s Peptelligence® and ProPerma® oral peptide and small molecule delivery technologies.

New CEO, Daniel A. Camardo, and Management to Host Conference Call on March 15, 2022.

Laurent Pharmaceuticals Inc. today announced that Luminis Health Research Institute in Annapolis MD, USA, has dosed the first patient in the Phase 3 expansion of the RESOLUTION Phase 2/3 clinical trial evaluating the efficacy of the novel COVID-19 oral antiviral LAU-7b.

PAVmed Inc., a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc., announced the appointment of prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors.

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its fourth quarter and full year 2021 financial results before the market opens on Tuesday, March 1, 2022.

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company, announced its results for the financial year ended December 31, 2021, and strategic decisions to optimize the long-term value of its two business pillars, anti-infectives and oncology.